Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 331

1.

Dual-energy contrast-enhanced spectral mammography (CESM).

Daniaux M, De Zordo T, Santner W, Amort B, Koppelstätter F, Jaschke W, Dromain C, Oberaigner W, Hubalek M, Marth C.

Arch Gynecol Obstet. 2015 Mar 27. [Epub ahead of print]

PMID:
25814297
2.

Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance.

Brennan DJ, Hackethal A, Mann KP, Mutz-Dehbalaie I, Fiegl H, Marth C, Obermair A.

BMC Cancer. 2015 Feb 6;15:33. doi: 10.1186/s12885-015-1028-0.

3.

Carboplatin and nonpegylated liposomal doxorubicin in primary advanced or recurrent endometrial cancer: a phase 2 trial conducted by AGO Austria.

Volgger B, Zeimet AG, Reinthaller A, Petru E, Schauer C, Klein M, Sevelda-Schwarzgruber U, Bogner G, Wolfram G, Marth C.

Int J Gynecol Cancer. 2015 Feb;25(2):257-62. doi: 10.1097/IGC.0000000000000352.

PMID:
25611899
4.

Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications.

Vergote IB, Marth C, Coleman RL.

Cancer Metastasis Rev. 2015 Mar;34(1):41-52. doi: 10.1007/s10555-014-9539-8.

PMID:
25564455
5.

Surgical and systemic management of endometrial cancer: an international survey.

Fotopoulou C, Kraetschell R, Dowdy S, Fujiwara K, Yaegashi N, Larusso D, Casado A, Mahner S, Herzog TJ, Kehoe S, Vergote I, Miller DS, Marth C, Fujii S, Sehouli J.

Arch Gynecol Obstet. 2015 Apr;291(4):897-905. doi: 10.1007/s00404-014-3510-3. Epub 2014 Oct 15.

PMID:
25315381
6.

Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study.

Sehouli J, Reinthaller A, Marth C, Reimer D, Reimer T, Stummvoll W, Angleitner-Boubenizek L, Brandt B, Chekerov R.

Br J Cancer. 2014 Oct 14;111(8):1519-25. doi: 10.1038/bjc.2014.443. Epub 2014 Sep 16.

PMID:
25225907
7.

Incorporation of pazopanib in maintenance therapy of ovarian cancer.

du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, Pignata S, Fujiwara K, Vergote I, Colombo N, Mirza MR, Monk BJ, Kimmig R, Ray-Coquard I, Zang R, Diaz-Padilla I, Baumann KH, Mouret-Reynier MA, Kim JH, Kurzeder C, Lesoin A, Vasey P, Marth C, Canzler U, Scambia G, Shimada M, Calvert P, Pujade-Lauraine E, Kim BG, Herzog TJ, Mitrica I, Schade-Brittinger C, Wang Q, Crescenzo R, Harter P.

J Clin Oncol. 2014 Oct 20;32(30):3374-82. doi: 10.1200/JCO.2014.55.7348. Epub 2014 Sep 15.

PMID:
25225436
8.

Getting the whole picture: adding patient-reported outcomes to adjuvant endocrine treatment evaluation in premenopausal breast cancer patients.

Oberguggenberger A, Goebel G, Beer B, Oberacher H, Meraner V, Sztankay M, Sperner-Unterweger B, Zeimet AG, Marth C, Hubalek M, Holzner B.

Breast J. 2014 Sep-Oct;20(5):555-7. doi: 10.1111/tbj.12323. Epub 2014 Jul 8. No abstract available.

PMID:
25040193
9.

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.

Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Herzog TJ, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Tassoudji M, Navale L, Warner DJ, Oza AM.

Lancet Oncol. 2014 Jul;15(8):799-808. doi: 10.1016/S1470-2045(14)70244-X. Epub 2014 Jun 17.

PMID:
24950985
10.

Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients.

Muendlein A, Hubalek M, Geller-Rhomberg S, Gasser K, Winder T, Drexel H, Decker T, Mueller-Holzner E, Chamson M, Marth C, Lang AH.

Eur J Cancer. 2014 Aug;50(12):2134-41. doi: 10.1016/j.ejca.2014.05.007. Epub 2014 Jun 5.

PMID:
24910416
11.

Nucleosome repositioning links DNA (de)methylation and differential CTCF binding during stem cell development.

Teif VB, Beshnova DA, Vainshtein Y, Marth C, Mallm JP, Höfer T, Rippe K.

Genome Res. 2014 Aug;24(8):1285-95. doi: 10.1101/gr.164418.113. Epub 2014 May 8.

12.

Axillary Lymph Node Status in Early-Stage Breast Cancer Patients with Sentinel Node Micrometastases (0.2-2 mm).

Bargehr J, Edlinger M, Hubalek M, Marth C, Reitsamer R.

Breast Care (Basel). 2013 Jun;8(3):187-91. doi: 10.1159/000352090.

13.

Interactions of human peritoneal mesothelial cells with serous ovarian cancer cell spheroids--evidence for a mechanical and paracrine barrier function of the peritoneal mesothelium.

Stadlmann S, Feichtinger H, Mikuz G, Marth C, Zeimet AG, Herold M, Knabbe C, Offner FA.

Int J Gynecol Cancer. 2014 Feb;24(2):192-200. doi: 10.1097/IGC.0000000000000036.

PMID:
24407573
14.

Endometroid carcinoma developing in endometriosis over the symphysis pubis.

Peer M, Fellner W, Seeber BE, Zeimet AG, Marth C.

Gynecol Oncol Case Rep. 2013 Sep 10;6:45-6. doi: 10.1016/j.gynor.2013.08.001. eCollection 2013.

15.

Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.

Vergote IB, Jimeno A, Joly F, Katsaros D, Coens C, Despierre E, Marth C, Hall M, Steer CB, Colombo N, Lesoin A, Casado A, Reinthaller A, Green J, Buck M, Ray-Coquard I, Ferrero A, Favier L, Reed NS, Curé H, Pujade-Lauraine E.

J Clin Oncol. 2014 Feb 1;32(4):320-6. doi: 10.1200/JCO.2013.50.5669. Epub 2013 Dec 23.

16.

L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.

Zeimet AG, Reimer D, Huszar M, Winterhoff B, Puistola U, Azim SA, Müller-Holzner E, Ben-Arie A, van Kempen LC, Petru E, Jahn S, Geels YP, Massuger LF, Amant F, Polterauer S, Lappi-Blanco E, Bulten J, Meuter A, Tanouye S, Oppelt P, Stroh-Weigert M, Reinthaller A, Mariani A, Hackl W, Netzer M, Schirmer U, Vergote I, Altevogt P, Marth C, Fogel M.

J Natl Cancer Inst. 2013 Aug 7;105(15):1142-50. doi: 10.1093/jnci/djt144. Epub 2013 Jun 18. Erratum in: J Natl Cancer Inst. 2013 Nov 20;105(22):1763.

17.

Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trial.

Seebacher V, Hofstetter G, Polterauer S, Reinthaller A, Grimm C, Schwameis R, Taucher S, Wagener A, Marth C, Concin N.

Br J Cancer. 2013 Jul 9;109(1):215-8. doi: 10.1038/bjc.2013.282. Epub 2013 Jun 13.

18.

Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer.

Fehm T, Banys M, Rack B, Janni W, Marth C, Blassl C, Hartkopf A, Trope C, Kimmig R, Krawczyk N, Wallwiener D, Wimberger P, Kasimir-Bauer S.

Int J Gynecol Cancer. 2013 Jun;23(5):839-45. doi: 10.1097/IGC.0b013e3182907109.

PMID:
23694981
19.

Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.

Chekerov R, Braicu I, Castillo-Tong DC, Richter R, Cadron I, Mahner S, Woelber L, Marth C, Van Gorp T, Speiser P, Zeillinger R, Vergote I, Sehouli J.

Int J Gynecol Cancer. 2013 Feb;23(2):268-75. doi: 10.1097/IGC.0b013e31827de6b9.

PMID:
23358178
20.

Conservative management of abnormally invasive placenta: four case reports.

Ramoni A, Strobl EM, Tiechl J, Ritter M, Marth C.

Acta Obstet Gynecol Scand. 2013 Apr;92(4):468-71. doi: 10.1111/aogs.12079. Epub 2013 Feb 14.

PMID:
23330969
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk